Latigo Biotherapeutics (NASDAQ:LTGO) Upgraded by Guggenheim to “Strong-Buy” Rating

Guggenheim upgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks reports.

Several other equities research analysts have also commented on the stock. Wall Street Zen raised shares of Latigo Biotherapeutics to a “hold” rating in a research report on Saturday, August 15th. The Goldman Sachs Group started coverage on shares of Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $73.00 price objective for the company. Leerink Partners assumed coverage on Latigo Biotherapeutics in a report on Tuesday. They issued an “outperform” rating and a $36.00 target price on the stock. Finally, Jefferies Financial Group started coverage on Latigo Biotherapeutics in a report on Tuesday. They set a “buy” rating and a $50.00 price target for the company. Four investment analysts have rated the stock with a Strong Buy rating, According to MarketBeat, Latigo Biotherapeutics has a consensus rating of “Strong Buy” and a consensus price target of $52.25.

Latigo Biotherapeutics Price Performance

Latigo Biotherapeutics stock opened at $22.26 on Tuesday. Latigo Biotherapeutics has a one year low of $17.22 and a one year high of $25.93.

Insiders Place Their Bets

In related news, Director James B. Tananbaum acquired 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the director directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. The trade was a 7.49% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of the stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the insider directly owned 2,008,024 shares in the company, valued at approximately $36,144,432. The trade was a 7.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Key Stories Impacting Latigo Biotherapeutics

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Multiple analyst upgrades: Leerink Partners, Jefferies Financial Group, Guggenheim, and Goldman Sachs each upgraded Latigo to “strong-buy.” The broad agreement among analysts may improve investor confidence and increase demand for LTGO shares.
• Positive Sentiment: Goldman Sachs initiates Buy rating: Analyst Salveen Richter cited Latigo’s differentiated non-opioid pain platform and Nav1.8 pipeline, along with the potential for significant peak sales. The thesis suggests investors see commercial opportunity in Latigo’s approach to pain treatment without opioids. Salveen Richter Initiates Buy on Latigo for Differentiated Non-Opioid Pain Platform and Nav1.8 Pipeline with Strong Peak Sales Potential
• Neutral Sentiment: Investor focus remains on the pipeline: Latigo’s valuation and future stock performance will likely depend on clinical progress, regulatory milestones, and whether its Nav1.8 candidates can demonstrate meaningful efficacy and safety in pain indications.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.